QT Imaging Holdings Inc

QT Imaging Holdings Inc(QTI)股票分析

$2.030

-0.039 (-1.93%)收盤時

Loading chart…
最高
2.150
開盤
2.070
成交量加權均價
2.06
成交量
28.49K
市值
—
最低
2.010
成交金額
58.78K
企業價值/稅息折舊攤銷前利潤(TTM)
-1.66

QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology.

AI 分析 of QT Imaging Holdings Inc (QTI)

買進

QT Imaging Holdings Inc (QTI) presents a compelling buy opportunity at the current price of $2.03, especially considering its recent 103% revenue growth in Q2 2026, which indicates strong market demand. The RSI is at a low 19.071, suggesting the stock is oversold and may rebound. However, the main risk is the significant net income loss of $11.07 million in Q2 2026, which investors should monitor closely.

估值指標

QT Imaging Holdings Inc(QTI)目前預期本益比為 0.00,5 年平均預期本益比為 0.00。

預期本益比

嚴重低估
5 年均值 P/E
0.00
目前P/E
0.00
高估
0.00
低估
0.00

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-0.96
目前EV/EBITDA
-1.66
高估
2.00
低估
-3.93

預期股價營收比

合理
5 年均值 P/S
0.18
目前P/S
0.53
高估
0.54
低估
-0.19

事件時間軸

2026-10-07 (ET)

09:00:00

QT Imaging Partners with NXC Imaging for National Purchasing Agreement

2026-09-17 (ET)

09:00:00

QT Imaging Appoints Mark Winkler as Chief Medical Officer

2026-08-12 (ET)

16:30:00

QT Imaging Reports Q2 Revenue of $7.4M, Below Estimates

2026-08-04 (ET)

09:00:00

QT Imaging Appoints New VPs to Advance U.S. Sales Strategy

2026-07-29 (ET)

09:00:00

QT Imaging Appoints Julia Albright as Chief Science Officer

資訊

QTI 常見問題 —— 由 Alphio AI 解答

QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology. It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).

QT Imaging Holdings Inc (QTI) presents a compelling buy opportunity at the current price of $2.03, especially considering its recent 103% revenue growth in Q2 2026, which indicates strong market demand. The RSI is at a low 19.071, suggesting the stock is oversold and may rebound. However, the main risk is the significant net income loss of $11.07 million in Q2 2026, which investors should monitor closely.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易